EXPERIENCE WITH A TRANSFUSION RECIPIENT EDUCATION-PROGRAM ABOUT HEPATITIS-C

ABSTRACT: Shortly after test kits for antibodies to the hepatitis C virus (HCV) were licensed in May of 1990, our medical community undertook a public education program encouraging previous transfusion recipients to see their physicians about the wisdom of being tested for anti‐HCV. In response, 1034 samples were received for testing. All samples repeatably reactive (RR) with anti‐HCV enzyme‐linked immunoassay (EIA) were tested further with a research recombinant immunoblot assay (RIBA). Overall, 76 of the 1034 (7.4%) recipient samples were RR and 64 of these (84.2%) were reactive with RIBA. Recipients transfused prior to surrogate testing (alanine aminotransferase [ALT] and anti‐hepatitis B core [anti‐HBc]) in 1986 showed a 8.6 percent reactivity with RIBA and those transfused after surrogate testing showed a 4.8 percent reactivity, a 44 percent reduction. Of the 57 recipient samples reactive with RIBA and suitable for assay, 11 (19.3%) had an elevated ALT. Among 76 randomly selected blood donors with RR EIAs studied for comparison with recipients, 20 (26.3%) were reactive with RIBA, 9 of which had an abnormal surrogate test that would have disqualified them. ALT concentrations were abnormal in 6 (30%) of the donors who were reactive on RIBA. We conclude that an education program that encourages previous transfusion recipients to seek medical advice about anti‐HCV testing is practical from the standpoint of the blood center. We believe more widespread implementation of similar programs should be considered. The findings also suggest that, when available, supplemental testing should be offered to blood donors with RR EIAs before they are counseled about permanent deferral because of anti‐HCV testing and to transfusion recipients identified by programs such as the one described. 1990 AABB